Published August 5, 2020
Follow our Medicare Coronavirus News page for related information on coronavirus (COVID-19) and its impact on Medicare beneficiaries.
President Trump issued an executive order on July 24 intended to lower prescription drug prices for Medicare by linking drug costs to the prices paid for the same drug in other countries. The order also allows Medicare beneficiaries to purchase medication imported from Canada.
The order that ties prescription drugs to international benchmarks, known as the “most-favored-nations rule,” will not go into effect until Aug. 24. Pharmaceutical companies have until then to come up with alternative measures for lowering the costs of their drugs.
Health officials estimate the move can save Medicare $17 billion in the first five years. Medicare spent $335 billion on prescription drugs in 2018.
There were additional action items included in Trump’s recent orders.
One measure involves stripping away legal protections for reimbursements that drug manufacturers make to middlemen and insurance plans that provide drug coverage through Medicare or Medicaid.
Because these reimbursements are typically based on the price of the drug, drugmakers are incentivized to charge higher drug prices. Trump’s orders would implement a flat-fee reimbursement.
Another aspect of the executive orders requires health centers that use the federal drug discount program to pass on any resulting savings on insulin or insulin pens to patients.
The executive order was not well received by everyone. Drugmakers and democrats had concerns about the effects the executive orders could have.
Several top pharmaceutical companies requested a White House meeting concerning the issue. The meeting was scheduled for July 28 but was later cancelled after major drug lobbies refused to send representatives.
Learn more about Medicare news and how the 2020 election may affect beneficiaries.